Xelyra Biotech De-Risks R&D with AI, Signals Major Move in $200B Longevity Market
Body: (WILMINGTON, DE) – In the high-stakes world of biotechnology, Xelyra Biotech is making waves with a shrewd strategy that could become a new industry standard. By leveraging in silico (computer simulation) trials for its flagship anti-aging formula, Lipo405, the company has effectively stress-tested its product’s potential before committing to costly, multi-year human trials. This […]
Continue Reading